Induced Pluripotent Stem Cells
(iPSCs) Market
Induced Pluripotent Stem Cells (iPSCs) Market
Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Induced Pluripotent Stem Cells (iPSCs) Market Size and Growth
The global Induced Pluripotent Stem Cells (iPSCs) market is experiencing significant growth due to increasing research and development activities in regenerative medicine and drug discovery. The market size is expected to reach USD 2.83 billion by 2026, with a CAGR of 8.3% during the forecast period.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Fujifilm Holding Corporation (CDI)
◍ ReproCELL
◍ Astellas Pharma Inc
◍ Ncardia
◍ Cell Inspire Biotechnology
◍ Sumitomo Dainippon Pharma
◍ Pluricell Biotech
◍ Fate Therapeutics, Inc
The Induced Pluripotent Stem Cells (iPSCs) Market is highly competitive with key players such as Fujifilm Holding Corporation (CDI), ReproCELL, Astellas Pharma Inc, Ncardia, Cell Inspire Biotechnology, Sumitomo Dainippon Pharma, Pluricell Biotech, and Fate Therapeutics, Inc.
These companies utilize iPSCs for drug discovery, regenerative medicine, and cell therapy applications, providing innovative solutions for various medical conditions. They contribute to the growth of the iPSCs market through research and development, collaborations, and commercialization of iPSC-based products.
- Fujifilm Holding Corporation (CDI) - $134.8 million
- ReproCELL - $60.7 million
- Fate Therapeutics, Inc - $40.1 million
Request Sample Report
Market Segmentation
By Application
Academic Research ◍ Drug Development and Discovery ◍ Toxicity Screening
Regenerative Medicine
Others
Request Sample Report
By Product
Human iPSCs
Mouse iPSCs
Market Growth
Request Sample Report
$ X Billion USD
